Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report

Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Midori, Kira, Satoru, Kamiyama, Manabu, Ihara, Tatsuya, Sato, Takeshi, Mitsui, Takahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284398/
https://www.ncbi.nlm.nih.gov/pubmed/35846514
http://dx.doi.org/10.1016/j.eucr.2022.102158
_version_ 1784747554327494656
author Hara, Midori
Kira, Satoru
Kamiyama, Manabu
Ihara, Tatsuya
Sato, Takeshi
Mitsui, Takahiko
author_facet Hara, Midori
Kira, Satoru
Kamiyama, Manabu
Ihara, Tatsuya
Sato, Takeshi
Mitsui, Takahiko
author_sort Hara, Midori
collection PubMed
description Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of cisplatin and etoposide for 6 months had a certain effect. However, his cancer progressed, and he took genetic screening exams. It revealed that his tumor mutational burden was high, and pembrolizumab was started. In this report, we suggested several new treatments.
format Online
Article
Text
id pubmed-9284398
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92843982022-07-16 Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report Hara, Midori Kira, Satoru Kamiyama, Manabu Ihara, Tatsuya Sato, Takeshi Mitsui, Takahiko Urol Case Rep Oncology Neuroendocrine prostate cancer (NEPC) is rare, with short overall survival, and no established standard therapy. Therefore, the management of NEPC is often challenging. We report a case of a 63-year-old male diagnosed with NEPC and treated with multimodal examinations and therapies. Chemotherapy of cisplatin and etoposide for 6 months had a certain effect. However, his cancer progressed, and he took genetic screening exams. It revealed that his tumor mutational burden was high, and pembrolizumab was started. In this report, we suggested several new treatments. Elsevier 2022-07-08 /pmc/articles/PMC9284398/ /pubmed/35846514 http://dx.doi.org/10.1016/j.eucr.2022.102158 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Hara, Midori
Kira, Satoru
Kamiyama, Manabu
Ihara, Tatsuya
Sato, Takeshi
Mitsui, Takahiko
Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
title Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
title_full Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
title_fullStr Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
title_full_unstemmed Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
title_short Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
title_sort neuroendocrine prostate cancer treated with multimodal examination and therapy: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284398/
https://www.ncbi.nlm.nih.gov/pubmed/35846514
http://dx.doi.org/10.1016/j.eucr.2022.102158
work_keys_str_mv AT haramidori neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport
AT kirasatoru neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport
AT kamiyamamanabu neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport
AT iharatatsuya neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport
AT satotakeshi neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport
AT mitsuitakahiko neuroendocrineprostatecancertreatedwithmultimodalexaminationandtherapyacasereport

Ejemplares similares